Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the ...

(NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A ...

Biohaven Ltd. BHVN shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an ...

Ocugen’s model fair value holds at US$11.43 per share, with no change to the underlying price target despite fresh clinical ...

BTIG raised its price target on Abivax to $175 from $150 and maintained a Buy rating. ・Wedbush said that it remains concerned about how the FDA will view cancer risk and the potential for a Black Box ...

At the event, Novo Nordisk also announced that U.S. prescriptions for the pill-based version of Wegovy just hit 3 million.

A comprehensive 5-day professional simulation mimicking an enterprise Healthcare Data Analyst role. Transitions banking ETL data discipline into healthcare data governance, clinical diagnostics, and ...

Research Capital analyst Andre Uddin says Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, ...

NeOnc Technologies Holdings (NASDAQ:NTHI) is entering one of the most significant periods in its corporate history ...

Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy. The healthcare giant has been swept up in a ...

Investing.com -- Spruce Biosciences Inc (NASDAQ:SPRB) shares climbed 3.2% in after-hours trading Monday following the presentation of long-term data for its MPS IIIB treatment and a new analyst ...